INTRODUCTION
Homocysteine (Hcy) is a non-protein forming sulphur aminoacid, synthesized from methionine. Once synthesized, Hcy may be either remethylated to reform methionine or catabolized through the transsulfuration pathway to form cysteine and more terminal products.
In 1969, McCully reported post-mortem evidence of an extensive arterial thrombosis and atherosclerosis in two children with hyperhomocysteinemia and hyperhomocystinuria. Therefore he proposed hyperhomocysteinemia as a possible cause of atherosclerotic vascular disease (1) .
Hyperhomocysteinemia can be toxic for the endothelium; it enhances vascular smooth muscle cell proliferation, increases platelet aggregation, and acts on coagulation cascade and fibrinolysis, directly inducing a prothrombotic environment, or acting with other risk factors in creating this condition (2) . Hcy acts as a prooxidant agent via the autoxidation of free thiols leading to superoxide production as well as through molecular targeting.
There is an epidemiologically proven link between uremia and hyperhomocysteinemia.
Uremia can be considered a model of accelerated ar teriosclerosis in which the high mor tality rate is mainly due to the cardiovascular disease (CVD). This epidemiological datum cannot be entirely explained by traditional risk factors, but by untraditional ones, among which there is hyperhomocysteinemia. It has been suggested to consider mild hyperhomocysteinemia as a CVD risk factor in the general population and in a number of acquired conditions such as renal failure, in which Hyc levels can range from moderate (16 to 30 µmol/L) to intermediate (30 to 100 µmol/L) (3) .
The cause and the underlying mechanisms responsible for this still remain unclear. However, there is evidence that hyperhomocysteinemia is related to a defective Hyc renal metabolism (4), and it seems unlikely to be the result of reduced urinary excretion (5) . Among the consequences of hyperhomocysteinemia in renal failure there is an impaired protein and DNA methylation, with an alteration in the allelic expression of genes regulated through this mechanism (6) .
It has also been suggested that the loss of watersoluble vitamins in the dialysis fluid may account for the increased Hyc levels in end-stage renal disease (ESRD).
Hyperhomocysteinemia and hemodialysis
In hemodialysis (HD) patients, the CVD mortality is 10-20 fold greater than in the general population, even after stratification by age, gender, race, and the presence of diabetes (7) . Hyperhomocysteinemia is frequently found in HD patients. In most studies, > 90% of dialysis patients have hyperhomocysteinemia, and the mean and median values of tHcy are between 20-25 µmol/L. This range is generally higher than the normal range reported for the general population (< 13.5 µmol/L ) (8) (9) (10) .
It has been proposed that this high prevalence of hyperhomocysteinemia in HD patients is one of reasons for the high rate of CVD in these individuals.
Whether hyperhomocysteinemia predicts cardiovascular outcome in HD patients was examined in few studies. Bostom et al demonstrated that the cardiovascular risk was 3.6 fold higher in patients with plasma values of Hcy greater than 27 µmol/L than in those displaying levels below this threshold (9). Moustapha et al found a 1% risk increase for each 1 µmol/L increase in plasma Hcy concentration. Also, in their study, Hcy was 59% higher in HD patients who had fatal and non fatal cardiovascular events, and the cardiovascular risk was independent of traditional risk factors (10) .
Mallamaci and colleagues reported that a 10 µmol/L
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The International Journal of Artificial Organs / Vol. 28 / no. 3, 2005/ pp. 207-210 Hyperhomocysteinemia in hemodialysis patients: Is it a risk factor for cardiovascular disease? increase in plasma Hcy concentration was associated with a 35% increase in the incident risk of fatal atherothrombotic events. Combined analysis of fatal and non fatal atherothrombotic events confirmed that Hcy was an independent predictor of cardiovascular mortality (11) . In a study by Buccianti and colleagues, Hcy was a strong independent mortality predictor in HD patients with a 3% increase in mortality for each 1 µmol/L increase in plasma Hcy concentration (12) . A study to define the influence of sex on the prevalence of conventional risk factors in HD patients, showed that male HD patients have significantly higher Hcy levels compared to female HD patients. This finding may account for the different cardiovascular risk between these two populations (13) .
In the pediatric population on dialysis or with chronic renal failure, Hcy levels are generally in the intermediate range (14, 15) . Hyperhomocysteinemia is associated with cardiovascular risk and even if cardiovascular disease is quite rare in this population, an approximately four fold increased risk of ischemic stroke exists (16) .
Hcy exists in plasma as protein-bound and as free forms. More than 70% of plasma Hcy is protein-bound, mainly to albumin. Its percentage in patients with ESRD before starting dialysis treatment is similar to that in the general population, whereas it is slightly greater in patients on HD (17) .
There is a strong association between inflammation and malnutrition in patients with ESRD, and serum albumin level is low in both these conditions. Also it is known that inflammation, cardiovascular disease and diabetes mellitus are associated with hypoalbominemia and a lower degree of hyperhomocysteinemia. Serum albumin is considered a key index of nutritional status, and it is commonly used to assess protein malnutrition, based on the concept that the level of serum albumin reflects the visceral protein status. Some authors demonstrated that patients with ESRD, in whom the prevalence of hyperhomocysteinemia was very high, showed Hcy levels strongly related to those of serum albumin, and patients with malnutrition had lower levels of both Hcy and serum albumin than those with a normal nutritional status. A higher absolute level of plasma Hcy in HD patients appeared to be associated with a lower prevalence of CVD and better survival, possibly related to increased protein intake, better nutritional status and higher serum albumin level. This apparently paradoxical association between Hcy and CVD does not strictly conflict with the thesis that hyperhomocysteinemia is a risk factor for CVD (18, 19) .
Recently Suliman et al reported that tHcy level and total cysteine are influenced by nutritional status and are interrelated with serum albumin and plasma amino acids levels and were lower in patients with inflammation. The high prevalence of inflammation, malnutrition, diabetes mellitus,and CVD, associated with low serum albumin concentration, is the possible explanation for the reverse association between tHcy level in patients starting renal replacement therapy and mor tality during dialysis treatment (20) .
Data from Busch et al, who studied patients with chronic kidney disease, patients on HD treatment and renal transplant recipients, provided evidence that conventional risk factors such as ESRD, diabetes, as well as elevated levels of the considered risk factor CRP, seem to play a more important role for cardiovascular outcome in patients with chronic renal failure than hyperhomocysteinemia and AGEs (21) .
Other studies found that in manteinance HD patients, hospitalization and mortality rates were significantly higher in patients with lower tHcy levels. Hence, tHcy may be a more exclusive nutritional biomarker in HD patients with no association with inflammation (22) .
Homocysteine and different membranes
Treatment with various dialyzers with different flux and in particular procedures using high-flux dialyzers have produced contrasting results. Procedures using low-flux dialyzers have shown a very moderate effect on Hcy postdialysis reduction. In a study by House et al, no difference has been observed between low-flux and high-flux dialyzers (23) . Lasseur et al suggested that the depletion in folate induced by high-flux/ high-efficiency dialysis could mask the potential decrease of serum Hcy through a greater extraction of the aminoacid with this technique. The Hcy concentration can be lowered only with the concomitant use of high-flux membrane and folate supplementation (24) . Positive results were reported by Baragetti et al using the acetate free-biofiltration technique (25) . Other studies show that HD with super flux dialyzers is more effective in reducing plasma Hcy levels than high flux ones (26, 27) . Gonella et al demonstrated that hemodiafiltration appeared to remove Hcy efficiently and the plasmatic levels of the aminoacid were generally normalized by adjusting the dose of vitamin B12 and B6, and using a folinic acid supplementation (28) . Double chamber hemodialfiltration with reinfusion of ultrafiltrate regenerated through a charcoal-resin cartridge (HFR-ON LINE) is a novel method which combines the processes of diffusion, convection and adsorbance. Splendiani et al suggest that HFR-ON LINE might represent an ideal procedure for lowering plasma Hcy levels in HD patients not only through a likely reduction of uremic toxins, but also through a removal of the aminoacid by adsorbance into the charcoal-resin cartridge (29) .
In conclusion HD with super-flux dialyzers and HFR-ON LINE are effective in reducing plasma Hcy levels. Whether long-term normalization of homoysteinemia will result in an improvement of endothelial dysfunction and reduction of CVD in chronic hemodialysis patients deserves further study.
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